BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS)

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.48) per share which beat the ana

Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027

Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report)'s stock price rose 15.4% during mid-day t

Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical co

Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolst

Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its A

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreat

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreat

Highly experienced biotechnology executive and board member will assist Kalaris in achieving its nex

BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS)

BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS)

Wedbush analyst Yun Zhong initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Outperf

Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Out

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the ana

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track t

Top analysts change outlook on top names, check analyst ratings page for all changes. Keybanc initia

Morgan Stanley analyst Judah Frommer initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) wit

Up to $100,000,000Kalaris Therapeutics, Inc.Common StockWe have entered into a sales agreement with

https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.44) per share which beat the ana

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; p

Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical com

Chardan Capital analyst Daniil Gataulin initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS)

Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH1

Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash positi

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS)

Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical company dedicated to th

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1,

Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nas

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.64) per share which beat the ana

Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by ye

Citizens analyst Jonathan Wolleben initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with

Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to th

Highly experienced biopharma financial officer joins leadership team  CFO hire bolsters Kalaris' lea

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kal

Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with